Patient and cancer baseline characteristics
| Characteristic | Treatment (No. of patients) | |||||
|---|---|---|---|---|---|---|
| RP (n = 73) | P (n = 75) | Total (n = 148) | ||||
| No. | % | No. | % | No. | % | |
| Gender | ||||||
| Male | 48 | 66.0 | 46 | 61.3 | 87 | 63.5 |
| Age, years | ||||||
| Median | 56.2 | 53.5 | 55.3 | |||
| Range | 25–71 | 27–74 | 25–74 | |||
| < 60 | 63 | 86.3 | 59 | 78.7 | 122 | 82.4 |
| ≥ 60 | 10 | 13.7 | 16 | 11.3 | 26 | 17.6 |
| ECOG | ||||||
| 0 | 1 | 1.4 | 2 | 2.7 | 3 | 2.0 |
| 1 | 68 | 93.2 | 69 | 92.0 | 137 | 92.6 |
| 2 | 4 | 6.4 | 4 | 5.4 | 8 | 5.4 |
| Primary tumor site | ||||||
| GE junction | 3 | 4.1 | 3 | 4.0 | 6 | 4.1 |
| Fundus | 5 | 6.8 | 6 | 8.0 | 11 | 7.4 |
| Antrum | 55 | 75.3 | 49 | 65.3 | 104 | 70.2 |
| Body | 10 | 13.7 | 17 | 22.7 | 27 | 18.2 |
| No. of organs involved | ||||||
| 1 | 2 | 2.7 | 1 | 1.3 | 3 | 2.0 |
| 2 | 7 | 9.6 | 4 | 5.3 | 11 | 7.4 |
| > 2 | 65 | 89.0 | 70 | 93.3 | 135 | 91.2 |
| Prior therapy | ||||||
| XELOX | 45 | 61.7 | 49 | 65.3 | 94 | 63.5 |
| SOX | 13 | 17.8 | 12 | 16.0 | 25 | 16.9 |
| ECF-like | 13 | 17.8 | 13 | 17.3 | 26 | 17.6 |
| Other | 2 | 2.7 | 1 | 1.3 | 3 | 2.0 |
RP, raltitrexed plus paclitaxel; P, paclitaxel.